Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1Plasma cell 1Head & Neck 1Dermatologic 1

Conditions

Pancreatic Neoplasms 7Sarcoma 4Hypoxia 4Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Melanoma 2Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 6pimonidazole 4fluoroazomycin arabinoside 4TH 302 4Radiotherapy 4Propofol 3Injections 3Positron Emission Tomography Computed Tomography 2Drug Therapy 2Blood Specimen Collection 2Bacterial Load 2pomalidomide 1pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1fludarabine 1alovudine 1Tirapazamine 1Thoracotomy 1Thoracic Surgery, Video-Assisted 1Temozolomide 1Surgical Procedures, Operative 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Pancreaticoduodenectomy 1Paclitaxel 1Oxygen 1Nitroglycerin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hypoxia × TH 302 × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00495144 2012-07-27

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Completed
129 enrolled

Hypoxia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡